Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Eurosurveillance Année : 2021

Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021

Résumé

Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.
Fichier principal
Vignette du fichier
eurosurv-26-26-1.pdf (329.72 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03278110 , version 1 (05-07-2021)

Licence

Paternité

Identifiants

Citer

Cécile Tran Kiem, Alessio Andronico, Paolo Bosetti, Juliette Paireau, Lise Alter, et al.. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. Eurosurveillance, 2021, 26 (26), ⟨10.2807/1560-7917.es.2021.26.26.2100533⟩. ⟨hal-03278110⟩
136 Consultations
49 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More